Therapeutic Nuclear Medicines Market Size, Share, Growth, and Industry Analysis, By Type (Radium-223, Lutetium-177, Iodine-131, Other), By Application (Thyroid, Bone Metastasis, Lymphoma, Other), Regional Insights and Forecast to 2035

Therapeutic Nuclear Medicines Market Overview

The global Therapeutic Nuclear Medicines Market size estimated at USD 3988.55 million in 2026 and is projected to reach USD 24164.57 million by 2035, growing at a CAGR of 22.16% from 2026 to 2035.

The Therapeutic Nuclear Medicines Market is expanding due to rising adoption of targeted radionuclide therapies for oncology, cardiology, and other chronic disease treatments. The market includes radiopharmaceuticals using isotopes such as Lutetium-177, Yttrium-90, Iodine-131, and Actinium-225 for precision treatment. More than 60 countries have nuclear medicine facilities supporting therapeutic applications, while over 10 million nuclear medicine procedures are performed globally each year. Increasing demand for personalized medicine.

The USA Therapeutic Nuclear Medicines Market is witnessing strong expansion due to increasing cancer treatment adoption and advanced radiopharmaceutical infrastructure. The country has more than 5,000 nuclear medicine departments and performs over 20 million diagnostic and therapeutic nuclear medicine procedures annually. Approximately 1.9 million new cancer cases are identified each year in the USA, increasing demand for targeted radionuclide therapies. Around 70% of major oncology centers are integrating precision medicine approaches, including radioligand therapies. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 65% of market growth is influenced by rising cancer prevalence, with nearly 55% of therapeutic nuclear medicine demand linked to oncology applications and around 45% driven by precision treatment adoption.
• Major Market Restraint: Around 40% of industry limitations are associated with isotope supply constraints, while nearly 35% of manufacturers face challenges related to regulatory approvals and approximately 25% experience production infrastructure barriers.
• Emerging Trends: Nearly 60% of new research programs focus on targeted alpha therapies, while about 50% of pharmaceutical developments involve Lutetium-177 applications and approximately 30% emphasize Actinium-225-based treatments.
• Regional Leadership: North America represents nearly 45% of global therapeutic nuclear medicine adoption, Europe contributes around 30%, Asia-Pacific accounts for approximately 20%, and other regions represent nearly 5% of demand.
• Competitive Landscape: Around 70% of market activity is concentrated among major radiopharmaceutical developers, while approximately 55% of innovation investments focus on isotope production, therapy platforms, and clinical expansion.
• Market Segmentation: Oncology applications represent nearly 75% of therapeutic nuclear medicines usage, while cardiovascular and other therapeutic applications contribute approximately 25% of market utilization across healthcare facilities.
• Recent Development: Around 65% of recent industry developments involve radioligand therapy advancements, while approximately 45% focus on supply chain improvements and nearly 35% target next-generation radioactive isotope technologies.

Therapeutic Nuclear Medicines Market Latest Trends

The Therapeutic Nuclear Medicines Market Trends are strongly influenced by increasing adoption of radioligand therapies, targeted alpha therapies, and personalized oncology treatments. More than 70% of therapeutic nuclear medicine research activities are focused on cancer applications, particularly prostate cancer and neuroendocrine tumors. Lutetium-177-based therapies represent nearly 50% of current clinical development activity due to their targeted radiation delivery capability. The growing availability of advanced imaging technologies has improved patient selection, with nearly 60% of oncology programs integrating molecular imaging and radionuclide therapy approaches.

Another major Therapeutic Nuclear Medicines Market Analysis trend is the expansion of isotope production capacity and global supply networks. Around 40% of industry investments are directed toward improving radioactive isotope availability, while approximately 35% of companies are developing next-generation alpha emitters such as Actinium-225. Increasing collaboration between pharmaceutical companies, research institutions, and healthcare providers is accelerating clinical adoption, with more than 100 therapeutic radiopharmaceutical trials progressing across different disease categories.

Therapeutic Nuclear Medicines Market Dynamics

DRIVER

"Rising Adoption of Targeted Cancer Therapies"

The major driver of the Therapeutic Nuclear Medicines Market Growth is the increasing demand for targeted cancer treatments that provide localized radiation delivery with reduced damage to healthy tissues. Oncology applications account for nearly 75% of therapeutic nuclear medicine utilization globally, with prostate cancer and neuroendocrine tumors representing major treatment areas. 

RESTRAINTS

"Limited Radioisotope Supply and Production Challenges"

A major restraint affecting the Therapeutic Nuclear Medicines Market is the limited availability of critical medical isotopes required for therapeutic applications. Around 40% of industry participants identify isotope supply chain limitations as a significant operational challenge. Production of advanced radionuclides such as Actinium-225 and Lutetium-177 requires specialized nuclear facilities, with fewer than 50 major global production centers supporting large-scale isotope availability. 

OPPORTUNITY

"Expansion of Personalized Medicine and Next-Generation Radiopharmaceuticals"

The Therapeutic Nuclear Medicines Market Opportunities are increasing due to rapid development of personalized medicine platforms and next-generation radiopharmaceutical technologies. More than 60% of ongoing research activities are focused on targeted alpha therapies and advanced radionuclide delivery systems. Pharmaceutical companies are investing in new isotope production capabilities. 

CHALLENGE

"High Infrastructure Requirements and Regulatory Complexity"

The Therapeutic Nuclear Medicines Market faces challenges due to complex regulatory requirements, high infrastructure investments, and specialized workforce needs. Approximately 30% of healthcare facilities experience difficulties in establishing dedicated nuclear medicine therapy units because of advanced radiation safety requirements. Around 35% of industry stakeholders identify regulatory approval processes as a major challenge affecting product commercialization timelines.

Therapeutic Nuclear Medicines Market Segmentation

The Therapeutic Nuclear Medicines Market Segmentation is categorized by type and application based on radionuclide characteristics, therapeutic mechanisms, and clinical usage areas. By type, the market includes Radium-223, Lutetium-177, Iodine-131, and other advanced radioactive isotopes. By application, therapeutic nuclear medicines are primarily used in oncology, endocrine disorders, bone metastasis treatment, and other targeted disease therapies. Oncology applications account for nearly 75% of overall therapeutic nuclear medicine utilization, while advanced radionuclide therapies continue gaining adoption due to improved precision, personalized treatment capabilities, and increasing demand for targeted cancer management solutions.

Download Free Sample to learn more about this report.

BY TYPE

Radium-223: Radium-223 represents an important segment of the Therapeutic Nuclear Medicines Market due to its targeted application in treating bone-related metastatic cancers, particularly prostate cancer with skeletal involvement. This alpha-emitting radionuclide provides localized radiation exposure with limited impact on surrounding healthy tissues. Approximately 25% of therapeutic nuclear medicine research activities involving bone-targeted treatments focus on alpha-emitting isotopes such as Radium-223. The isotope has demonstrated significant adoption among oncology centers because of its ability to deliver high-energy alpha particles over a short distance, improving treatment precision. More than 60 countries have incorporated bone-targeted radiopharmaceutical therapies into cancer management programs. 

Lutetium-177: Lutetium-177 is one of the fastest-growing segments within the Therapeutic Nuclear Medicines Market due to its broad application in radioligand therapy for prostate cancer and neuroendocrine tumors. Approximately 50% of current therapeutic radiopharmaceutical development programs involve Lutetium-177-based solutions because of its favorable radiation characteristics and targeted delivery capability. The isotope emits beta particles suitable for destroying cancer cells while also producing gamma emissions that support treatment monitoring. More than 70% of global radioligand therapy research activities focus on improving Lutetium-177-based treatment platforms. 

Iodine-131: Iodine-131 remains a widely utilized therapeutic isotope segment in the Therapeutic Nuclear Medicines Market, especially for thyroid-related disorders and differentiated thyroid cancer treatment. More than 70% of radioactive iodine therapies worldwide are associated with thyroid disease management, making Iodine-131 one of the most established radionuclides in clinical practice. The isotope has been used across thousands of hospitals and nuclear medicine facilities due to its proven therapeutic effectiveness and established handling procedures. Approximately 40% of endocrine-focused nuclear medicine treatments rely on radioactive iodine-based approaches. Rising thyroid cancer detection rates and increasing screening programs are supporting continued demand for Iodine-131 therapies. 

Other: The Other segment of the Therapeutic Nuclear Medicines Market includes emerging radionuclides such as Actinium-225, Yttrium-90, and other specialized isotopes developed for targeted therapies. This segment is gaining importance due to increasing research activity in next-generation alpha and beta-emitting treatments. Approximately 60% of early-stage therapeutic nuclear medicine research programs are focused on advanced isotopes beyond traditional radionuclides. Actinium-225-based therapies are receiving significant attention because of their high-energy alpha emission properties, with more than 30 clinical programs evaluating alpha-targeted treatment approaches.

BY APPLICATION

Thyroid: The thyroid application segment represents one of the most established areas within the Therapeutic Nuclear Medicines Market due to the extensive use of radioactive iodine therapies for thyroid disorders and differentiated thyroid cancer treatment. Iodine-131 remains the primary therapeutic isotope used in this application because of its ability to selectively accumulate in thyroid tissue and deliver targeted radiation. More than 70% of radioactive therapeutic procedures related to endocrine disorders are associated with thyroid disease management. Globally, thyroid cancer accounts for more than 800,000 diagnosed cases annually, increasing demand for effective nuclear medicine treatment options. Approximately 40% of endocrine-focused nuclear medicine departments provide radioactive iodine therapy as a standard treatment service. 

Bone Metastasis: The bone metastasis application segment is a major contributor to the Therapeutic Nuclear Medicines Market due to increasing adoption of radionuclide therapies for managing cancer-related skeletal complications. Bone metastasis commonly occurs in advanced cancers, particularly prostate, breast, and lung cancers, creating demand for targeted radiopharmaceutical treatments. More than 60% of patients with advanced prostate cancer and approximately 70% of patients with advanced breast cancer may experience bone-related metastatic complications during disease progression. Therapeutic isotopes such as Radium-223 and other bone-seeking radionuclides are increasingly used to deliver localized radiation treatment and reduce pain associated with metastatic bone lesions. 

Lymphoma: The lymphoma application segment is gaining importance in the Therapeutic Nuclear Medicines Market due to increasing utilization of radioimmunotherapy and targeted radionuclide treatments for blood cancers. Therapeutic nuclear medicines are used to deliver radiation directly to lymphoma cells by combining radioactive isotopes with targeting molecules. More than 500,000 new lymphoma cases are diagnosed globally each year, creating demand for advanced treatment approaches. Approximately 20% of therapeutic radiopharmaceutical research programs are focused on hematologic cancers, including different lymphoma subtypes. Radioimmunotherapy approaches using targeted radioactive compounds have demonstrated significant clinical value, especially for patients who require alternative treatment options after conventional therapies. 

Other: The Other application segment of the Therapeutic Nuclear Medicines Market includes treatments for neuroendocrine tumors, liver cancer, prostate cancer, and other rare diseases requiring targeted radionuclide therapy. This segment is expanding due to increasing adoption of radioligand therapy platforms and advanced isotope-based treatment methods. Neuroendocrine tumor applications represent a significant portion of this segment, with more than 100,000 new cases identified globally each year. Approximately 50% of emerging therapeutic nuclear medicine clinical programs focus on expanding applications beyond traditional thyroid and bone treatments. Lutetium-177-based therapies are increasingly utilized in this category due to their ability to target specific tumor markers while minimizing damage to surrounding tissues.

Therapeutic Nuclear Medicines Market Regional Outlook

The Therapeutic Nuclear Medicines Market Regional Outlook highlights strong adoption across North America, Europe, Asia-Pacific, and Middle East & Africa due to increasing demand for targeted radiopharmaceutical therapies and advanced oncology treatments. North America holds the leading position with approximately 45% of the global market share, supported by advanced healthcare infrastructure, strong research activities, and high availability of nuclear medicine facilities. Europe accounts for nearly 30% market share due to established radiopharmaceutical production networks and increasing cancer treatment applications. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Therapeutic Nuclear Medicines Market with approximately 45% global market share due to advanced nuclear medicine infrastructure, increasing adoption of precision oncology, and strong availability of therapeutic radiopharmaceutical technologies. The region includes more than 5,000 nuclear medicine facilities and contributes significantly to global radioligand therapy adoption. The United States represents the largest contributor within North America, supported by high cancer treatment demand, extensive clinical research programs, and advanced isotope production capabilities. Around 70% of major oncology institutions in the region are integrating targeted radionuclide therapies into cancer care programs. More than 1.9 million new cancer cases annually in the United States are supporting demand for innovative therapeutic nuclear medicine solutions. Canada also contributes to regional growth through expanding nuclear medicine departments and research initiatives. Approximately 50% of North American therapeutic radiopharmaceutical development programs focus on oncology applications, including prostate cancer, neuroendocrine tumors, and metastatic diseases. 

EUROPE

Europe holds approximately 30% share of the Therapeutic Nuclear Medicines Market due to established nuclear medicine networks, strong research capabilities, and increasing adoption of targeted radionuclide therapies. The region has more than 3,000 nuclear medicine departments supporting diagnostic and therapeutic applications across major healthcare systems. European countries are actively expanding radiopharmaceutical manufacturing capabilities to improve isotope availability and reduce supply limitations. Around 60% of European therapeutic nuclear medicine research programs focus on oncology treatments, including prostate cancer, thyroid cancer, and neuroendocrine tumor therapies. Germany, the United Kingdom, France, and Italy represent key contributors due to advanced healthcare infrastructure and increasing investment in precision medicine. More than 40% of European oncology centers are integrating radioligand therapy approaches into specialized treatment programs. The growing adoption of Lutetium-177 and Actinium-225-based therapies is supporting innovation across the region. European healthcare providers are also focusing on improving patient access to nuclear medicine treatments through expanded clinical facilities and trained medical professionals. 

GERMANY Therapeutic Nuclear Medicines Market

Germany represents one of the leading countries in the European Therapeutic Nuclear Medicines Market, accounting for approximately 10% of the global market share. The country has a strong nuclear medicine infrastructure with more than 250 specialized nuclear medicine facilities supporting diagnostic and therapeutic procedures. Increasing adoption of radioligand therapy, radioactive iodine treatment, and targeted radionuclide applications is strengthening market development. Germany performs thousands of therapeutic nuclear medicine procedures annually, supported by advanced hospitals, research institutions, and skilled healthcare professionals. Approximately 35% of European nuclear medicine research activities involve German healthcare organizations and academic institutions. The country is focusing on improving isotope availability, expanding radiopharmaceutical production capabilities, and increasing access to personalized oncology treatments. Rising demand for prostate cancer therapies, neuroendocrine tumor treatments, and thyroid disorder management is supporting market expansion. 

UNITED KINGDOM Therapeutic Nuclear Medicines Market

The United Kingdom Therapeutic Nuclear Medicines Market is expanding steadily and represents approximately 8% of the global market share due to increasing adoption of targeted radionuclide therapies and advanced cancer treatment approaches. The country has more than 200 nuclear medicine facilities supporting therapeutic and diagnostic applications across hospitals and specialized treatment centers. Growing utilization of Lutetium-177 therapies for prostate cancer and neuroendocrine tumors is driving demand for advanced radiopharmaceutical solutions. Around 40% of nuclear medicine research activities in the United Kingdom focus on oncology-related therapeutic applications. The healthcare system is investing in improved radiopharmaceutical access, isotope supply management, and expansion of specialist treatment capabilities. Increasing cancer incidence, rising demand for personalized medicine, and development of clinical research programs are supporting the United Kingdom Therapeutic Nuclear Medicines Market Growth. 

ASIA-PACIFIC

The Asia-Pacific Therapeutic Nuclear Medicines Market is witnessing increasing adoption and represents approximately 20% of the global market share, supported by rising healthcare investments, expanding oncology treatment infrastructure, and growing demand for targeted radiopharmaceutical therapies. The region includes more than 1,500 nuclear medicine facilities, with major contributions from China, Japan, South Korea, India, and Australia. Increasing cancer incidence across Asia-Pacific is creating demand for advanced therapeutic solutions, with more than 9 million new cancer cases reported annually across the region. Approximately 45% of nuclear medicine development activities in Asia-Pacific are focused on oncology applications, including prostate cancer, thyroid cancer, neuroendocrine tumors, and bone metastasis treatment. Countries are investing in isotope production facilities, specialized treatment centers, and advanced imaging technologies to improve patient access. Japan and China represent key contributors due to their advanced healthcare systems and expanding radiopharmaceutical research programs. 

JAPAN Therapeutic Nuclear Medicines Market

Japan holds a significant position in the Asia-Pacific Therapeutic Nuclear Medicines Market and accounts for approximately 7% of the global market share. The country has a highly developed healthcare system with more than 1,000 nuclear medicine facilities supporting diagnostic and therapeutic applications. Japan has strong expertise in radioactive isotope utilization, particularly for thyroid treatment, oncology applications, and targeted radionuclide therapies. Approximately 40% of therapeutic nuclear medicine procedures in Japan are associated with cancer treatment applications, including thyroid cancer and advanced solid tumors. The increasing elderly population, with more than 28% of citizens aged above 65 years, is contributing to higher demand for advanced healthcare solutions. Japan is also expanding research activities focused on Lutetium-177 and other next-generation radionuclide therapies. Around 30% of Japanese nuclear medicine research programs involve personalized treatment approaches using molecular targeting technologies. 

CHINA Therapeutic Nuclear Medicines Market

China represents one of the fastest-growing countries in the Asia-Pacific Therapeutic Nuclear Medicines Market, contributing approximately 9% of the global market share. The country’s expanding oncology sector and increasing healthcare modernization are driving demand for targeted nuclear therapies. China records more than 4 million new cancer cases annually, creating significant demand for advanced treatment technologies including radiopharmaceutical therapies. The country has more than 700 nuclear medicine departments supporting diagnostic and therapeutic procedures across major hospitals. Approximately 50% of therapeutic nuclear medicine activities in China focus on oncology applications, including thyroid cancer, neuroendocrine tumors, and metastatic cancer treatments. China is increasing investments in domestic isotope production, radiopharmaceutical manufacturing, and nuclear medicine research capabilities. Around 35% of regional clinical research programs involving therapeutic radionuclides are conducted through Chinese healthcare institutions. 

MIDDLE EAST & AFRICA

The Middle East & Africa Therapeutic Nuclear Medicines Market accounts for approximately 5% of the global market share and is gradually expanding due to increasing investments in healthcare infrastructure, cancer treatment facilities, and nuclear medicine capabilities. The region has more than 300 nuclear medicine centers supporting diagnostic and therapeutic applications, with leading contributions from countries such as Saudi Arabia, United Arab Emirates, South Africa, and Egypt. Rising cancer prevalence, with more than 700,000 new cancer cases identified annually across the region, is increasing demand for targeted radiopharmaceutical therapies. Approximately 30% of healthcare development projects in major Middle Eastern countries include advanced oncology and nuclear medicine facilities. The region is improving access to therapeutic isotopes through international collaborations, specialized training programs, and expansion of radiation therapy services. Around 35% of nuclear medicine applications in the region focus on thyroid disorders, while oncology-based radionuclide therapies represent approximately 45% of utilization. Countries are investing in isotope production capabilities and modern healthcare technologies to reduce dependence on external supply chains. 

List of Key Therapeutic Nuclear Medicines Market Companies

• Novartis AG
• Bayer
• China Isotope and Radiation
• Q BioMed
• Curium Pharmaceuticals
• Jubilant DraxImage
• Dongcheng
• Lantheus
• Acrotech Biopharma
• Progenics Pharmaceuticals
• International Isotopes

Top Two Companies with Highest Share

• Novartis AG: Holds approximately 18% share of the Therapeutic Nuclear Medicines Market, supported by strong radioligand therapy capabilities, extensive oncology-focused product development, and broad adoption of targeted radionuclide treatments.
• Bayer: Accounts for nearly 12% market share due to its established presence in radiopharmaceutical therapies, advanced isotope-based treatment solutions, and growing global utilization of targeted cancer therapies.

Investment Analysis and Opportunities

Investment activities in the Therapeutic Nuclear Medicines Market are increasing due to rising demand for precision oncology treatments, advanced radiopharmaceutical platforms, and improved isotope production capabilities. Approximately 60% of current industry investments are focused on developing targeted radionuclide therapies, especially alpha and beta-emitting treatments for cancer management. Around 45% of investment initiatives are directed toward improving radioactive isotope supply chains, production facilities, and distribution networks. Pharmaceutical companies and biotechnology organizations are increasing funding toward clinical research, with nearly 50% of therapeutic nuclear medicine development programs concentrated on oncology applications. 

Emerging investment opportunities are also driven by increasing healthcare infrastructure development in Asia-Pacific, Middle East, and Latin American regions. Approximately 35% of healthcare organizations worldwide are planning expansions in nuclear medicine capabilities to improve access to advanced therapeutic treatments. More than 40% of new research collaborations focus on next-generation radionuclides, including Actinium-225 and Lutetium-177-based therapies. Investments in companion diagnostics, imaging technologies, and patient-specific treatment planning are supporting market advancement. Around 30% of companies operating in the nuclear medicine sector are expanding their research pipelines to include rare cancers and complex diseases. 

New Products Development

New product development in the Therapeutic Nuclear Medicines Market is focused on advanced radiopharmaceutical therapies, targeted alpha treatments, and improved radionuclide delivery systems. Approximately 65% of new therapeutic nuclear medicine research programs are focused on oncology applications, including prostate cancer, neuroendocrine tumors, and metastatic cancers. Lutetium-177-based therapies represent nearly 50% of ongoing product development activities due to increasing demand for precise tumor targeting and personalized treatment solutions. Around 35% of companies are developing innovative radiopharmaceutical combinations to enhance treatment effectiveness and reduce exposure to healthy tissues.

The development pipeline is also expanding with next-generation isotopes and improved manufacturing technologies. Approximately 40% of new product initiatives involve Actinium-225 and other alpha-emitting radionuclides designed for highly targeted cancer treatment. Around 30% of product development efforts focus on improving isotope availability, production efficiency, and treatment accessibility across healthcare systems. Pharmaceutical companies are investing in advanced molecular targeting platforms, with nearly 45% of research programs integrating companion diagnostics for patient selection. Increasing clinical trials, improved radiation delivery technologies, and growing demand for precision medicine are accelerating innovation within the Therapeutic Nuclear Medicines Market.

Five Recent Developments

• Novartis AG: In 2024, Novartis expanded its focus on radioligand therapy innovation with increased development activities in targeted cancer treatments. Approximately 60% of its nuclear medicine research initiatives were concentrated on oncology applications, including prostate cancer and neuroendocrine tumor therapies. 
• Bayer: In 2024, Bayer continued advancing radiopharmaceutical treatment solutions with a focus on targeted alpha and beta-emitting therapies. Around 45% of its nuclear medicine development activities were related to improving precision oncology applications. 
• Lantheus: In 2024, Lantheus enhanced its nuclear medicine portfolio by focusing on diagnostic and therapeutic radiopharmaceutical integration. Approximately 50% of development efforts were directed toward improving molecular imaging support for targeted therapies. 
• Curium Pharmaceuticals: In 2024, Curium Pharmaceuticals increased investments in radiopharmaceutical production and isotope availability improvements. Nearly 40% of its development activities focused on strengthening nuclear medicine supply capabilities and expanding therapeutic applications. 
• China Isotope and Radiation: In 2024, China Isotope and Radiation accelerated development of domestic radiopharmaceutical solutions to support expanding nuclear medicine demand. Approximately 55% of its innovation activities focused on oncology-related therapeutic applications and isotope technologies. 

Report Coverage Of Therapeutic Nuclear Medicines Market

The Therapeutic Nuclear Medicines Market Report Coverage provides a detailed assessment of market performance, industry trends, technological advancements, regional developments, and competitive activities across global healthcare systems. The report evaluates major therapeutic applications, including thyroid disorders, bone metastasis, lymphoma, neuroendocrine tumors, and other oncology-related treatments. Oncology applications represent approximately 75% of total therapeutic nuclear medicine utilization, while other medical applications contribute nearly 25% of adoption.

The report includes regional analysis covering North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting market share distribution, infrastructure development, and adoption patterns. North America contributes approximately 45% of global market share, Europe accounts for nearly 30%, Asia-Pacific represents around 20%, and Middle East & Africa contributes approximately 5%. The coverage also examines competitive strategies, product development activities, investment trends, and manufacturing advancements among leading companies. Nearly 65% of recent industry developments are associated with radioligand therapy advancements, isotope production improvements, and next-generation therapeutic platforms.